RT Journal Article
SR Electronic
T1 Real-World Experience of Deep Brain Stimulation Surgery in a Developing Southeast Asian Country
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.23.23294286
DO 10.1101/2023.08.23.23294286
A1 Dy Closas, Alfand Marl F.
A1 Tan, Ai Huey
A1 Tay, Yi Wen
A1 Hor, Jia Wei
A1 Toh, Tzi Shin
A1 Lim, Jia Lun
A1 Lew, Choey Yee
A1 Cham, Chun Yoong
A1 Yim, Carolyn Chue Wai
A1 Chee, Kok Yoon
A1 Ng, Chong Guan
A1 Lit, Lei Cheng
A1 Anuar, Anis Nadhirah Khairul
A1 Lange, Lara M.
A1 Fang, Zih-Hua
A1 Ciga, Sara Bandres
A1 Lohmann, Katja
A1 Klein, Christine
A1 Ahmad-Annuar, Azlina
A1 Muthusamy, Kalai Arasu
A1 Lim, Shen-Yang
YR 2023
UL http://medrxiv.org/content/early/2023/08/25/2023.08.23.23294286.abstract
AB Background The availability of deep brain stimulation (DBS), a highly efficacious treatment for several movement disorders, remains low in developing countries, with scarce data available on utilization and outcomes.Objectives We characterized the DBS cohort and outcomes at a Malaysian quaternary medical centre.Methods A retrospective chart review was done on DBS-related surgery at the University of Malaya, including clinico-demographic, genetics, and outcomes data focusing on post-operative medication reduction and complications.Results 149 Parkinson’s disease (PD) patients underwent DBS targeting the subthalamic nucleus. Six had globus pallidus internus DBS (primarily for dystonia). Only 16.1% of cases were government-funded. Of the 133 PD patients operated in the past decade (2013-2022), 25 (18.8%) had disease duration <5 years. At 6-12 months post-DBS, median levodopa-equivalent daily dosage (LEDD) reduction was 440.5 [418.9] mg/day, corresponding to a reduction of ≥50% and ≥30% in 42.2% and 69.8% of patients, respectively. LEDD reductions were larger in the early-onset and short-duration subgroups. Three patients (1.9% of 155) had symptomatic intracranial hemorrhage, resulting in stroke in two. Pathogenic monogenic or GBA1 variants were detected in 12/61 (19.7%) of patients tested, mostly comprising the “severe” GBA1 variant p.L483P (14.8%).Conclusion This is the largest report on DBS from Southeast Asia. The procedures were effective, and complication rates on par with international norms. Our study found a high frequency of GBA1-PD; and included a substantial number of patients with short-duration PD, who had good outcomes. It also highlights the inequity of access to device-aided therapy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors declare that there are no conflicts of interest relevant to this work. This work was supported by a grant awarded to SYL from the Ministry of Higher Education Malaysia (FRGS/1/2020/SKK0/UM/01/2) and the University of Malaya Parkinson's Disease and Movement Disorders Research Program (PV035-2017) awarded to SYL and AHT. AMD was supported by a grant from the Global Parkinson's Genetics Project (GP2) funded by the Michael J. Fox Foundation. Financial Disclosures for the Previous 12 months: SYL receives grants from the Michael J. Fox Foundation and the Ministry of Education Malaysia Fundamental Research Grant Scheme. He serves on the Editorial Board for Neurotorium. He has received honoraria for talks sponsored by Medtronic, and the International Parkinson & Movement Disorder Society (MDS). AHT receives grants from the Michael J. Fox Foundation, Ministry of Education Malaysia Fundamental Research Grant Scheme, and Toray Science Foundation Science & Technology Grant. She has received honoraria for talks sponsored by Sanofi, and the International Parkinson & Movement Disorder Society (MDS). KAM is a proctor for Medtronic and has received honoraria from Medtronic.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the Medical Ethics Committee, UM.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.